Relay Therapeutics, Inc. Diluted Shares Outstanding (Weighted Average)
Relay Therapeutics, Inc. (RLAY) reported Diluted Shares Outstanding (Weighted Average) of 112.23 million shares for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-23.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2023-02-23
- Relay Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2022-12-31 was 121.06M shares, a 17.83% increase year-over-year.
- Relay Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2022-09-30 was 110.91M shares, a 19.65% increase year-over-year.
- Relay Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2021-12-31 was 102.75M shares.
- Relay Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2021-09-30 was 92.69M shares.
- Relay Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2022 was 112.23M shares, a 17.97% increase from fiscal 2021.
- Relay Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2021 was 95.14M shares, a 123.22% increase from fiscal 2020.
- Relay Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2020 was 42.62M shares.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2022-12-31 | 121.06M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | 115.98M shares derived: average of 2 quarters · filed 2023-02-23 | 112.23M shares 10-K · filed 2023-02-23 | |
| 2022-09-30 | 110.91M shares 10-Q · filed 2022-11-03 | 109.29M shares 10-Q · filed 2022-11-03 | ||
| 2021-12-31 | 102.75M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | 97.72M shares derived: average of 2 quarters · filed 2023-02-23 | 95.14M shares 10-K · filed 2023-02-23 | |
| 2021-09-30 | 92.69M shares 10-Q · filed 2022-11-03 | 92.60M shares 10-Q · filed 2022-11-03 | ||
| 2020-12-31 | 42.62M shares 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |